Review Article
Bone Loss Prevention of Bisphosphonates in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Table 1
Summary of the basic characteristics of the bisphosphonate and control groups.
| | Trial | Year | Intervention | Bisphosphonate administration | Control | Number of patients
(intervention/
control) | Age
(intervention/
control) | BMD (±SD g/cm2)
lumbar spine
(intervention/
control) | BMD (±SD g/cm2)
Hip
(intervention/
control) | BMD (±SD g/cm2)
-score
lumbar spine
(intervention/
control) | BMD (±SD g/cm2)
-score
lumbar spine
(intervention/
control) | Duration |
| | Bartram et al. | 2003 | Pamidronate | 30 mg/3 months i.v | No placebo | 37/37 | /
| / | / | / | / | 12 | | Haderslev et al. | 2000 | Alendronate | 10 mg/day p.o | Placebo | 15/17 | / | / | / | / | / | 12 | | Siffledeen et al. | 2005 | Etidronate | 400 mg/14 days p.o | No placebo | 71/72 | / | / | / | / | / | 24 | | Soo et al. | 2012 | risedronate | 35 mg/day p.o | Placebo | 45/43 | / | / | / | / | / | 24 | | Tirpitz et al. | 2003 | Ibandronate | 1 mg/3 months i.v | No placebo | 35/13 | / | NA | NA | / | / | 27 | | Klaus et al. | 2011 | Ibandronate | 1 mg/3 months i.v | No placebo | 54/32 | / | / | / | / | / | 42 | | Henderson et al. | 2006 | risedronate | 5 mg/day p.o | Placebo | 30/31 | / | / | / | NA | NA | 12 | | Palomba et al. | 2005 | risedronate | 35 mg/week p.o | Placebo | 45/45 | / | / | / | NA | NA | 12 | | van Bodegraven et al. | 2014 | risedronate | 35 mg/week p.o | Placebo | 64/67 | / | / | / | / | / | 24 | | Abitbol et al. | 2007 | Clodronate | 900 mg/3 months i.v | Placebo | 33/34 | 30/30 | NA | NA | NA | NA | 12 | | Kitazaki et al. | 2009 | alendronate | 5 mg/day p.o | No placebo | 19/20 | / | / | NA | NA | NA | 12 |
|
|
